In a double-blind, randomized, placebo-controlled trial, dapagliflozin, as an adjunct to insulin, resulted in significant reductions in glomerular filtration rate and measures of glycemia when compared to placebo in youth with type 1 diabetes.
- Farid H. Mahmud
- Petter Bjornstad
- David Z. I. Cherney
